VIPoma natural history, complications and prognosis

Revision as of 00:40, 30 July 2020 by WikiBot (talk | contribs) (Bot: Removing from Primary care)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

VIPoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating VIPoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

VIPoma natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of VIPoma natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on VIPoma natural history, complications and prognosis

CDC on VIPoma natural history, complications and prognosis

VIPoma natural history, complications and prognosis in the news

Blogs on VIPoma natural history, complications and prognosis

Directions to Hospitals Treating VIPoma

Risk calculators and risk factors for VIPoma natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Madhu Sigdel M.B.B.S.[2]Parminder Dhingra, M.D. [3] Homa Najafi, M.D.[4]

Overview

If left untreated, patients with VIPoma may progress to develop watery diarrhea, abdominal pain, bloating, nausea, vomiting, skin rash, backache, flushing, and lethargy. Common complications of VIPoma include metastasis, cardiac arrest from low blood potassium level, and dehydration. The presence of metastasis is associated with a particularly poor prognosis among patients with VIPoma, with a 5 year survival rate of 60%.

Natural History

Complications

Common complications of VIPoma include:[2][3]

Prognosis

References

  1. Natanzi, Naveed; Amini, Mazyar; Yamini, David; Nielsen, Shawn; Ram, Ramin (2009). "Vasoactive Intestinal Peptide Tumor". Scholarly Research Exchange. 2009: 1–7. doi:10.3814/2009/938325. ISSN 1687-8299.
  2. J. V. VERNER & A. B. MORRISON (1958). "Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia". The American journal of medicine. 25 (3): 374–380. doi:10.1016/0002-9343(58)90075-5. PMID 13571250. Unknown parameter |month= ignored (help)
  3. A. Ayub, M. Zafar, A. Abdulkareem, M. A. Ali, T. Lingawi & A. Harbi (1993). "Primary hepatic vipoma". The American journal of gastroenterology. 88 (6): 958–961. PMID 8389095. Unknown parameter |month= ignored (help)
  4. Nilubol N, Freedman EM, Quezado MM, Patel D, Kebebew E (2016). "Pancreatic Neuroendocrine Tumor Secreting Vasoactive Intestinal Peptide and Dopamine With Pulmonary Emboli: A Case Report". J Clin Endocrinol Metab. 101 (10): 3564–3567. doi:10.1210/jc.2016-2051. PMC 5052354. PMID 27583474.


Template:WikiDoc Sources